Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | $45.00 | Outperform | Noble Capital Markets |
| 9/1/2021 | $78.00 | Buy | HC Wainwright & Co. |
STAFFORD, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its financing strategy. The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for Q1 2026 exceeded the Company's Q1 2026 cash burn rate, leading to a Q1 2026 cash balance of approximately $10.5 million as of March 31, 2026. The above
STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes increases the market for GLSI-100 by an a
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US. The Phase III clinical trial has recently been activated at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States – specifically at its network sites in Los Angeles and Orange counties, Arizona, Atlanta, and Illinois. Principal investigator at City of Hop
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00
HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00
Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00
NT 10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)
10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)
SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)